The latest news, announcements and press releases from Antengene Corp.
HONG KONG and BRUSSELS - Antengene Corporation Limited and UCB announced today they have entered into a worldwide exclusive licensing agreement for ATG-201, a CD19/CD3 bispecific T-cell engager antibody targeting B cell-related autoimmune diseases, according to a press release statement.
Under the agreement, UCB receives worldwide exclusive rights to develop, manufacture and commercialize ATG-201. Antengene will receive $80 million in upfront and near-term milestone payments, comprising an initial $60 million upfront payment and an additional $20 million upon satisfaction of certain conditions. The company is eligible to receive over $1.1 billion in development, regulatory and sales milestones, plus tiered royalties on future net sales.
Shanghai and Hong Kong, PRC, February 25, 2026 — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, SEHK: 1877.HK; SSE: 688180). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene’s ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences’ JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types.
Antengene Corporation Limited (Antengene) has entered a global clinical collaboration with MSD (Merck & Co., Inc.) to evaluate the combination of ATG-022 and MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors.
This is the News section of the company profile page for Antengene Corp on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
